Publications
Detailed Information
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Hyo-Joon | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.date.accessioned | 2023-12-11T07:46:01Z | - |
dc.date.available | 2023-12-11T07:46:01Z | - |
dc.date.created | 2020-08-27 | - |
dc.date.created | 2020-08-27 | - |
dc.date.issued | 2012-03 | - |
dc.identifier.citation | Journal of Medical Virology, Vol.84 No.3, pp.424-430 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198646 | - |
dc.description.abstract | There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETV-resistant HBV with prior lamivudine (LAM) resistance, and either with or without previous ADV resistance. The cumulative probability of achieving a virological response (undetectable serum HBV DNA) was compared by KaplanMeier analysis and the Breslow method. Seventeen patients with ETV-resistant HBV who were treated with ETV/ADV combination therapy for at least 6 months at a tertiary care center, were included; seven had dual resistance to ETV and LAM [ADV-r(-) group] and 10 had triple resistance to ETV, LAM, and ADV [ADV-r(+) group]. The median follow-up period was 9 months (range, 623). A virological response was noted in seven patients after a median of 3 months (range, 312) of treatment; five in the ADV-r(-) group and two in the ADV-r(+) group. The cumulative probability of a virological response was significantly higher in the ADV-r(-) group than in the ADV-r(+) group (6 months cumulative probability, 57.1% vs. 11.1%). In conclusion, ETV/ADV combination therapy led to virological responses in five of seven patients with resistance to ETV and LAM, but a significantly poorer response in patients with prior ADV resistance than in those without prior ADV resistance. Therefore, ETV/ADV combination therapy could be a useful therapeutic option for ETV- and LAM-resistant HBV without prior ADV resistance. J. Med. Virol. 84:424430, 2012. (C) 2011 Wiley Periodicals, Inc. | - |
dc.language | 영어 | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/jmv.23229 | - |
dc.citation.journaltitle | Journal of Medical Virology | - |
dc.identifier.wosid | 000299071300007 | - |
dc.identifier.scopusid | 2-s2.0-84862953011 | - |
dc.citation.endpage | 430 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 424 | - |
dc.citation.volume | 84 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jun | - |
dc.contributor.affiliatedAuthor | Yoon, Jung-Hwan | - |
dc.contributor.affiliatedAuthor | Lee, Hyo-Suk | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LAMIVUDINE RESISTANCE | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordPlus | SUSCEPTIBILITY | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | SELECTION | - |
dc.subject.keywordPlus | MUTATION | - |
dc.subject.keywordPlus | KOREA | - |
dc.subject.keywordAuthor | entecavir resistance | - |
dc.subject.keywordAuthor | multidrug resistance | - |
dc.subject.keywordAuthor | rescue therapy | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.